Drug intelligence / Profile preview

balapiravir + peginterferon alfa-2a + ribavirin

Development stage: Discontinued
Lead developer: Roche
Modality: Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral, Subcutaneous

Overview

This combination consists of **balapiravir** (a small molecule oral prodrug, code name RO4588161, developed by Roche, also known as R-1626), **peginterferon alfa-2a** (a pegylated recombinant interferon alfa-2a protein, approved for hepatitis C), and **ribavirin** (a nucleoside analogue antiviral). - **Balapiravir** is a prodrug of R1479, designed to inhibit the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, halting viral RNA replication. - **Peginterferon alfa-2a** modulates immune response to enhance clearance of HCV-infected cells. - **Ribavirin** is a guanosine analogue that inhibits viral RNA synthesis and viral mRNA capping, with a broad antiviral mechanism. This triple combination was developed for chronic HCV infection but discontinued due to lack of efficacy and unacceptable toxicity of balapiravir at higher doses, such as lymphopenia. Primary indication: hepatitis C virus infection[1][3][5][7][9][2][4][10].

Other names: balapiravir + peginterferon alfa-2a + ribavirinR-1626 + peginterferon alfa-2a + ribavirin

Targets

IFNAR (Immune system modulation via type I interferon receptor)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on balapiravir + peginterferon alfa-2a + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on balapiravir + peginterferon alfa-2a + ribavirin.

Explore the full profile